Get the Stockscreener App
0.9104
0.96%
-0.002
Inflarx N V stock is traded at $0.9104, with a volume of 98,046.
It is down -0.96% in the last 24 hours and up +7.57% over the past month.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$0.9124
Open:
$0.91
24h Volume:
98,046
Relative Volume:
0.18
Market Cap:
$61.22M
Revenue:
-
Net Income/Loss:
$-46.12M
P/E Ratio:
-1.0535
EPS:
-0.8642
Net Cash Flow:
$-41.02M
1W Performance:
-3.21%
1M Performance:
+7.57%
6M Performance:
-42.45%
1Y Performance:
-26.54%
1-Day Range:
$0.8999
$0.9581
1-Week Range:
$0.8611
$0.9581
52-Week Range:
$0.7113
$1.94
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
0.9036 | 61.81M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.38 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.72 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
747.00 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.27 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.45 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-02-25 | Resumed | H.C. Wainwright | Buy |
| May-29-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx N V Stock (IFRX) Latest News
IFRX Earnings History & Surprises | EPS & Revenue Results | INFLARX NV (NASDAQ:IFRX) - ChartMill
Aug Macro: Whats the analyst consensus on InflaRx NV2025 Market Sentiment & Community Consensus Stock Picks - baoquankhu1.vn
InflaRx N.V. (NASDAQ:IFRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference - Bitget
Biotech InflaRx to stream March 9 Leerink healthcare fireside chat - Stock Titan
InflaRx Showcases Izicopan HS and CSU Data, Streamlines C5aR Strategy at Oppenheimer Conference - MarketBeat
InflaRx N.V. (IFRX) Presents at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceSlideshow - Seeking Alpha
IFRX Should I Buy - Intellectia AI
IFRX PE Ratio & Valuation, Is IFRX Overvalued - Intellectia AI
InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit - MarketBeat
IFRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Will InflaRx N.V. stock continue dividend increasesJuly 2025 Snapshot & Long-Term Safe Investment Ideas - mfd.ru
Is InflaRx N.V. (IF0) stock among top earnings playsPortfolio Update Summary & Growth Oriented Trading Recommendations - mfd.ru
Treasury Yields: Is InflaRx NV forming bullish engulfing patternsEarnings Risk Summary & Smart Investment Allocation Tips - baoquankhu1.vn
InflaRx N.V. (NASDAQ:IFRX) Receives $7.50 Consensus PT from Analysts - Defense World
Here's Why We're A Bit Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Situation - Sahm
InflaRx N.V. (NASDAQ:IFRX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
InflaRx launches public offering of shares and warrants - MSN
How strong is InflaRx N.V. stock revenue growthWeekly Profit Report & Growth Oriented Trading Recommendations - mfd.ru
InflaRx (NASDAQ:IFRX) Trading 10.4% HigherStill a Buy? - MarketBeat
Here's Why InflaRx (NASDAQ:IFRX) Must Use Its Cash Wisely - Yahoo Finance
History Review: Is InflaRx NV showing insider buyingWeekly Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Tech Rally: Can InflaRx NV sustain earnings growth2025 EndofYear Setup & Daily Technical Stock Forecast Reports - baoquankhu1.vn
InflaRx Announces Participation in February Investor Conferences - marketscreener.com
Can InflaRx N.V. deliver consistent dividendsTrade Risk Summary & Weekly Market Pulse Alerts - mfd.ru
Biotech firm InflaRx lines up two investor talks in February - Stock Titan
InflaRx NV Explodes After FDA Greenlight: Is IFRX the Biotech Underdog You’re Sleeping On? - AD HOC NEWS
Buyback Watch: Is InflaRx NV showing insider buyingJuly 2025 Levels & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Can InflaRx N.V. (IF0) stock sustain margin levelsMarket Performance Recap & Technical Analysis for Trade Confirmation - bollywoodhelpline.com
Is InflaRx N.V. stock positioned for digital transformationMarket Movers & Safe Entry Point Identification - bollywoodhelpline.com
Meme Stocks: Can InflaRx NV deliver consistent dividends2025 Pullback Review & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Bank Watch: Is Montauk Renewables Inc a potential multi baggerWatch List & Low Drawdown Momentum Ideas - baoquankhu1.vn
Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours - Intellectia AI
Bull Run: Why InflaRx N.V. (IF0) stock could rally stronglyJuly 2025 Levels & Weekly High Potential Stock Alerts - Bộ Nội Vụ
InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Pullback Watch: Will InflaRx NV stock recover faster than market2025 Key Highlights & Daily Profit Maximizing Tips - Bộ Nội Vụ
Is InflaRx N.V. stock a top pick in earnings season2025 Fundamental Recap & Intraday High Probability Setup Alerts - Улправда
Why InflaRx N.V. stock remains on buy listsWeekly Investment Recap & Reliable Breakout Stock Forecasts - Улправда
How InflaRx N.V. stock valuations compare to rivalsInflation Watch & Technical Pattern Recognition Alerts - Улправда
InflaRx Cuts Workforce and Refocuses Strategy on Lead Drug Izicopan to Extend Cash Runway to 2027 - TipRanks
Will InflaRx N.V. stock recover faster than market2025 Top Gainers & Advanced Swing Trade Entry Alerts - Улправда
Why is InflaRx Stock Falling Today?InflaRx (NASDAQ:IFRX) - Benzinga
InflaRx stock falls after announcing restructuring and pipeline prioritization By Investing.com - Investing.com India
InflaRx stock falls after announcing restructuring and pipeline prioritization - Investing.com
InflaRx to prioritize izicopan development, cuts workforce by 30% - Investing.com South Africa
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation - GlobeNewswire
What analysts say about InflaRx NV IF0 stockPrice Support Zones & Follow Top Performers in the Community - earlytimes.in
InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder - Sahm
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? - RTTNews
InflaRx (IFRX) stock: biotech battleground after a volatile quarter and shifting expectations - AD HOC NEWS
Inflarx N V Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):